Large gap with delayed quotes
Analysis date: 06.03.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 13.02.2026.
Interest
Weak
Weak
Two stars since 24.02.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 13.02.2026 at a price of 250.49.
Evaluation
Overvalued
Overvalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately overvalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 16.01.2026.
4wk Rel Perf
1.53%
1.53%
The four-week dividend-adjusted overperformance versus SP500 is 1.53%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 13.02.2026.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.70%.
Mkt Cap in $bn
17.60
17.60
With a market capitalization >$8bn, WEST PHARMACEUTICAL is considered a large-cap stock.
G/PE Ratio
0.77
0.77
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential:
LT P/E
23.30
23.30
The estimated PE is for the year 2028.
LT Growth
17.64%
17.64%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
13
13
Over the last seven weeks, an average of 13 analysts provided earnings per share estimates.
Dividend Yield
0.36%
0.36%
The twelve month estimated dividend yield represents 8.36% of earnings forecasts.
Beta
91
91
For 1% of index variation, the stock varies on average by 0.91%.
Correlation
0.44
0.44
43.66% of stock movements are explained by index variations.
Value at Risk
40.61
40.61
The value at risk is estimated at USD 40.61. The risk is therefore 16.52%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
09.08.2006
09.08.2006